Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1

Original document(41 pages) 中文版

Pyrazole carboxamides of structural formula (I) are selective inhibitors of the 11beta-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.

Application Number 申请号	200480022672	Application Date 申请日	2004.08.03
Title 名称	Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
Publication Number 公开号	1832741	Publication Date 公开日	2006.09.13
Approval Pub. Date		Granted Pub. Date
International Classification 分类号	A61K31/415,C07D231/16
Applicant(s) Name 申请人	Merck & Co. Inc.
Address 地址
Inventor(s) Name 发明人	Gao Ying-duo, Gu Xin, Kevin Nancy J.
Attorney & Agent 代理人	guo yu wang jingchao

Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
Dosage forms comprising ag013736
Treatment for alzheimer's disease and related conditions
2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity
Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
Combinations comprising staurosporines
Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
Viscosity-Stable bismuth-containing pharmaceutical compositions.
Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury and proliferation and/or differentiation of neural stem cells in injured spinal cord

Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.